BMI View: The vast majority of Namibia’s pharmaceutical needs will remain sourced from abroad,
however, domestic production of ARV drug nevirapine shows a commitment to achieving self-sufficiency in
terms of medicine production. However, this is unlikely to be achieved in the foreseeable future given the
limited production capacity among domestic companies including Fabupharm.
Headline Expenditure Forecasts
? Pharmaceuticals: NAD2.34bn (USD184mn) in 2015 to NAD2.56bn (USD172mn) in 2016; +9.4% in
local currency and -6.5% in US dollar terms. Forecast unchanged from last quarter in local currency
terms and revised downwards in USD terms.
? Healthcare: NAD11.38bn (USD895mn) in 2015 to NAD12.48bn (USD840mn) in 2016; +9.7% in local
currency and -6.2% in US dollar terms. Forecast revised slightly upwards from last quarter in local
currency terms and downwards in USD terms.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Namibia 2014-2020) 7
SWOT 9
Industry Forecast 10
Pharmaceutical Market Forecast 10
Table: Pharmaceutical Sales, Historical Data And Forecasts (Namibia 2012-2020) 12
Healthcare Market Forecast 12
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Namibia 2012-2020) 14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Namibia 2012-2020) 14
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Namibia 2012-2020) 14
Industry Risk Reward Index 15
Middle East and Africa Risk/Reward Index - Q2 2016 15
Namibia Risk/Reward Index 22
Rewards 22
Risks 22
Regulatory Review 24
Pharmaceutical Distribution 26
Market Overview 27
Healthcare Sector 28
Research & Development 31
Epidemiology 32
Demographic Forecast 34
Namibia - Demographic Forecast 34
Table: Population Headline Indicators (Namibia 1990-2025) 35
Table: Key Population Ratios (Namibia 1990-2025) 35
Table: Urban/Rural Population & Life Expectancy (Namibia 1990-2025) 36
Table: Population By Age Group (Namibia 1990-2025) 36
Table: Population By Age Group % (Namibia 1990-2025) 37
Glossary 39
Methodology 41
Pharmaceutical Expenditure Forecast Model 41
Healthcare Expenditure Forecast Model 41
Notes On Methodology 42
Risk/Reward Index Methodology 43
Index Overview 44
Table: Pharmaceutical Risk/Reward Index Indicators 44
Indicator Weightings 45

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Namibia 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Namibia 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Namibia 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Namibia 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Namibia 2012-2020)
Table: Population Headline Indicators (Namibia 1990-2025)
Table: Key Population Ratios (Namibia 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Namibia 1990-2025)
Table: Population By Age Group (Namibia 1990-2025)
Table: Population By Age Group % (Namibia 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators